Efalizumab for the Treatment of Moderate to Severe Plaque Psoriasis

@article{Jordan2005EfalizumabFT,
  title={Efalizumab for the Treatment of Moderate to Severe Plaque Psoriasis},
  author={Joseph K. Jordan},
  journal={Annals of Pharmacotherapy},
  year={2005},
  volume={39},
  pages={1476 - 1482}
}
OBJECTIVE: To review the pharmacology, efficacy, and safety of efalizumab for the treatment of moderate to severe plaque psoriasis. DATA SOURCES: A MEDLINE search (1966–May 2005%) using the key words hu1124, anti-CD11a, efalizumab, Raptiva, Xanelim, and psoriasis was conducted. References of identified articles were reviewed for additional citations. STUDY SELECTION AND DATA EXTRACTION: Clinical trials evaluating the pharmacology, efficacy, and safety of efalizumab for treatment of moderate to… Expand
Efalizumab
TLDR
Although initially favorable, the safety profile of efalizumab revealed the appearance of severe adverse events in long-term treated patients, leading to its withdrawal from the market. Expand
Topo-Proteomic in situ Analysis of Psoriatic Plaque under Efalizumab Treatment
TLDR
Topo-proteomic data provide new diversified insights into the pleiotropic cellular dynamics in psoriatic skin lesions under effective efalizumab treatment. Expand
The CD11a Binding Site of Efalizumab in Psoriatic Skin Tissue as Analyzed by Multi-Epitope Ligand Cartography Robot Technology
TLDR
It is demonstrated that efalizumab represents a treatment for psoriasis that primarily targets memory CD4+ and CD8+ T cells and has a high specificity for psoriatic disease activity. Expand
Visceral Leishmaniasis Infection in a Patient with Psoriasis Treated with Efalizumab
TLDR
The patient was living in Campania, southwest Italy, which has long been known to be endemic for VL and was treated intravenously with teicoplanin, ciprofloxacin, furosemide, albumin and folic acid and intramuscularly with vitamin B 12 . Expand
Psoriasis and psoriatic arthritis: clinical features and disease mechanisms.
TLDR
Newer therapies, such as the biologics, are providing more targeted approaches with potentially fewer systemic toxicities, providing control of disease symptoms and inhibiting progressive joint damage in those with arthritis, as well as improving long-term function and quality of life. Expand
Targeting integrin structure and function in disease.
TLDR
Conformational switches, including an internal ligand, which allosterically regulate the transition from low- to high-affinity ligand binding are reviewed, which brings greater focus to how integrins support various cellular functions and how they have been and may be targeted to develop novel drugs. Expand
Efalizumab‐induced autoimmune pancytopenia
  • W. Tom, M.D. Miller, +4 authors J. Obadiah
  • Medicine
  • The British journal of dermatology
  • 2006
TLDR
This work describes the first case of immune‐mediated pancytopenia in a patient treated with efalizumab, a recombinant, humanized monoclonal anti‐CD11a antibody used for the treatment of moderate to severe plaque psoriasis. Expand
A reappraisal of humoral immunity based on mechanisms of antibody-mediated protection against intracellular pathogens.
TLDR
Far from being understood, recent findings in AMI imply a system with unfathomable complexity and the field is poised for a long overdue renaissance. Expand
Molecular, Biologic, and Pharmacokinetic Properties of Monoclonal Antibodies: Impact of These Parameters on Early Clinical Development
TLDR
This review provides an overview of the molecular, biochemical, and pharmacokinetic properties and clinical development history of Mabs and details how these factors currently affect the scope and design of early clinical development strategies for these drug candidates. Expand
Absence of β2 Integrins Impairs Regulatory T Cells and Exacerbates CD4+ T Cell-Dependent Autoimmune Carditis
TLDR
Findings are consistent with a model in which the development of arthritis in K/BxN mice relies primarily on autoantibodies, whereas endocarditis depends on an additional contribution of effector T cells. Expand
...
1
2
...

References

SHOWING 1-10 OF 24 REFERENCES
Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial.
TLDR
In this 12-week study, efalizumab resulted in significant improvements in clinical end points, including physician-assessed and dermatology-specific patient-reported HRQL measures, in patients with moderate to severe plaque psoriasis. Expand
Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis.
TLDR
Extending efalizumab treatment from 12 to 24 weeks leads to improved efficacy and maintenance of quality of life with no evidence of cumulative toxic effects noted in patients with moderate to severe chronic plaque psoriasis. Expand
Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial.
TLDR
Twelve-week efalizumab treatment resulted in significant improvement; extension of therapy to 24 weeks resulted in additional improvement in patients who initially had not achieved PASI-75. Expand
Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasis.
TLDR
The majority of patients experienced sustained efficacy with no increase in toxicity, and patients will receive up to 36 months of continuous efalizumab. Expand
A novel targeted T-cell modulator, efalizumab, for plaque psoriasis.
TLDR
Efalizumab therapy resulted in significant improvements in plaque psoriasis in subjects with moderate-to-severe disease, and extending treatment from 12 to 24 weeks resulted in both maintenance and improvement of responses. Expand
Psoriasis as a model for T-cell-mediated disease: immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody.
TLDR
At doses of 0.3 mg/kg or more per week, intravenous efalizumab produced significant clinical and histologic improvement in psoriasis, which correlated with sustained serum efalIZumab levels and T-cell CD11a saturation and down-modulation. Expand
Considerations for assessing the cost of biologic agents in the treatment of psoriasis.
  • S. Rich
  • Medicine
  • Journal of managed care pharmacy : JMCP
  • 2004
TLDR
The biologic agents currently used in the treatment of psoriasis offer patients new hope for safe and effective therapy, and comparison of these agents by managed care decision makers requires consideration of characteristics that differentiate the agents. Expand
Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis.
TLDR
Targeting CD11a may improve psoriasis by inhibiting T-cell activation, T-cells emigration into the skin, and cytotoxic T- cell function. Expand
The effects of an anti-CD11a mAb, efalizumab, on allergen-induced airway responses and airway inflammation in subjects with atopic asthma.
TLDR
Blocking of LFA-1/intercellular adhesion module interactions by efalizumab inhibits the development of allergen-induced cellular inflammatory responses measured in induced sputum and might attenuate the late asthmatic response. Expand
Biological therapies in the systemic management of psoriasis: International Consensus Conference
TLDR
The limitations of current Psoriasis therapies, the value of biological therapies for psoriasis, and guidance regarding the incorporation of Biological therapies into clinical practice are discussed. Expand
...
1
2
3
...